Information Provided By: 
Fly News Breaks for April 11, 2019
MD
Apr 11, 2019 | 08:54 EDT
Jefferies analyst Jason Plagman lowered his price target for Mednax to $31 from $37 and keeps Hold rating on the shares. While the analyst believes the company is likely to post Q1 results slightly above consensus with in-line Q2 guidance, he sees a lack of near-term catalysts to push the stock significantly higher. Mednax faces structural headwinds to its organic growth and margins, as well as a slowing pace of acquisitions and limited balance sheet capacity, Plagman tells investors in a research note.
News For MD From the Last 2 Days
There are no results for your query MD
